Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0UL2L
|
||||
| Former ID |
DIB015995
|
||||
| Drug Name |
Lornoxicam
|
||||
| Synonyms |
CTX; Chlortenoxicam; Lorcam; Safem; Telos; Xefo; Xefo Rapid; HN-10000; TS-110; Ro-13-9297
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Migraine [ICD9: 346; ICD10:G43] | Approved | [1], [2] | ||
| Company |
Roche Holding AG
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C13H10ClN3O4S2
|
||||
| Canonical SMILES |
S1(=O)(=O)c2c(C(=C(N1C)C(=O)Nc1ncccc1)O)sc(c2)Cl
|
||||
| CAS Number |
CAS 70374-39-9
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Cyclooxygenase | Target Info | Modulator | [3], [2] | |
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT00997750) Efficacy and Safety of Lornoxicam in Patients With Acute Coronary Syndrome. U.S. National Institutes of Health. | ||||
| REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
| REF 3 | The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro. Inflamm Res. 1999 Jul;48(7):369-79. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.